Effects on PaCO2 Levels of Two Different Nasal Cannula in COPD Patients
NCT ID: NCT05528289
Last Updated: 2024-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2022-08-04
2023-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this randomized crossover physiological study is to investigate the effects on PaCO2 levels of two different nasal cannula ('Optiflow + Duet' interface vs "standard" nasal interface) in COPD patients with persistent hypercapnia following an acute severe exacerbation
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tolerance and Acute Effects of a New HFNT Nasal Cannula
NCT05182294
Asymmetrical Versus Conventional High-flow Nasal Cannula in Acute Respiratory Failure
NCT06204276
Non-invasive Ventilation Versus High Flow Oxygen
NCT03758508
Effect of Extracorporeal CO2 Removal in Stable Hypercapnic COPD Patients
NCT02260583
High Flow Nasal Cannula Versus Non-Invasive Ventilation in Exacerbations of Chronic Obstructive Pulmonary Disease
NCT03033251
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HFNC 40 L/min with conventional symmetric nasal cannula
The patients will be asked to breathe with HFNC at flow of 40 L/min with standard interface
AIRVO 2, the new asymmetric nasal cannula
The patients will be asked to breathe with HFNC at flow of 40 L/min with the new asymmetric nasal cannula
The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.
Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%.
HFNC 40 L/min with new asymmetric nasal cannula
The patients will be asked to breathe with HFNC at flow of 40 L/min with the new asymmetric nasal cannula
AIRVO 2, with conventional symmetric nasal cannula
The patients will be asked to breathe with HFNC at flow of 40 L/min with the standard cannula
The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.
Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AIRVO 2, with conventional symmetric nasal cannula
The patients will be asked to breathe with HFNC at flow of 40 L/min with the standard cannula
The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.
Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%.
AIRVO 2, the new asymmetric nasal cannula
The patients will be asked to breathe with HFNC at flow of 40 L/min with the new asymmetric nasal cannula
The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.
Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Persisting hypercapnia, despite having reached a stabilization in pH (i.e. pH\>7,35 and
* PaCO2\>50 mmHg on 3 consecutive measurements)
* Informed consent
Exclusion Criteria
* Previous diagnosis of Obstructive sleep apnea syndrome (OSAS)
* Chest wall disease
* Heart failure
* Severe hemodynamic instability ( need for amine support)
* Acute coronary syndrome (ACS)
* Severe arrhythmia
* Renal insufficiency
* Patients unable to protect respiratory airways
* Respiratory arrest and need for endotracheal intubation
* Pregnancy
* Need for sedation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
dr. Stefano Nava
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Policlinico di Sant'Orsola
Bologna, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
n° 174/2022/Disp/AOUBo
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.